JOIN OUR TEAM
In what is normally a slow–growing category in the 0.5%-3.0% range for year–over–year performance, the internal analgesics category witnessed much stronger–than–average growth rates in 2020. Consumers stocked up on pain relievers and fever reducers to be prepared for coronavirus. The overall internal analgesics category witnessed sales growth of more than 6.0%, with the Tylenol brand up nearly 40% and Motrin
The second half of 2017 saw a significantly higher incidence of cold and flu which helped propel sales of OTC cold and sinus medications, cough syrups, cough drops, and nasal decongestants. The OTC cold and sinus market grew 4.5% from 2016 to 2017, which is nearly three times the growth rate experienced in 2016. Not only
Rx-to-OTC switch brands continue to be major game changers on the OTC market, whether promoting strong gains or causing steep declines. Traditional OTC lines are delivering growth as they have expanded to meet consumer needs with the Centrum (Pfizer) and One-A-Day (Bayer) vitamin lines. Both of these lines using broad reaching marketing campaigns have had success with new product launches.
